Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
EH domain-binding protein 1 (EHBP1) is an adaptor protein widely expressed in mammalian tissues, containing a calponin homology (CH) domain for actin binding, an N-terminal C2 domain for membrane association, and a C-terminal bMERB domain for Rab8 family GTPase interaction[1][2][5]. EHBP1 regulates endocytic vesicle trafficking, particularly recycling endosomes and GLUT4-containing vesicles in adipocytes, by linking endosomes to the actin cytoskeleton[1][2][3]. Its molecular function is auto-inhibited until engagement with Rab8 family proteins, which releases the actin-binding CH domain and promotes vesicle movement or membrane tubulation[2]. EHBP1 collaborates with proteins like EHD1, EHD2, and Rab8/Rab10, and disruptions in this protein can affect metabolic processes and have been linked to cancer aggressiveness and development in model organisms[1][2][3][4].
For atorvastatin: anti-invasive effects in PTEN-positive prostate cancer cells require EHBP1; EHBP1 helps mediate interactions affecting membrane trafficking and cell invasion[2]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on EH domain-binding protein 1 (EHBP1).